Replies to post #6408 on International Stem Cell Corp. (ISCO)

[MyzStreet]

Great post thanks! I have researched many regenerative medicine companies in the last few years. I really like the subsidiaries (very rare to find in this space) and the tech here! I believe it has a great chance of becoming a giant or getting acquired. I’ve placed my bet and will continue to add along the way!
$ISCO

[Doctor_Hari_Seldon]

I would not put it past them to get this new product done and on the market by the end of the year. I guess we might have to add another product line to this now established hybrid of a company being revenue generating operational plus developmental, plus stage I/II clinical trials. They often get done what they say they are going to do. Kudos to ISCO. Keep building. Eventually the radars will see what you have achieved and reward you and your future patients.

This stock is so far under most radars that news really does not have the reach and thus the impact that it should.

IMHO the cons are:

-they always have low cash on hand.
-the cash burn rate is high (not super high), but still forces negative cash flow.
-due to the above the need for the owners to keep buying stock to fund the extra cash needs, and leads to the potential for significant dilution.
-the board they are on, placement and news reach keeps both good news somewhat hidden from the majority of potential investors.

IMHO the pros are:

-They have real technology that is not a scam and has significant potential in areas of critical medical needs.
-They have accomplished most of what they say they are going to do.
-They have used their developments to support their technology to produce viable products.
-They have real earnings from the marketing branches of their products in cell technology and skin care as separate entities.
-due to the above, they are one of the few developmental/clinical stage biotech companies that have any revenue generating arm at all. Thus some of their cash burn is funded through division earnings and they additionally gain valuable marketing experience and contacts.
-They have a multitude of patents, some more valuable than others. Patents are costly to get and maintain, but add to a companies intellectual property value and can be the key to future success or buyout value.
-their clinical stage I and II studies are done through a world renowned neurological research facility. (no company that has scam technology would be able to get their foot in the door with such reputable organizations)